The brain may be about to have its Ozempic moment
Drugmakers are betting that orexins, peptides that keep people awake, could become the next GLP-1, transforming treatment for brain-related ailments. Just as GLP-1 drugs like Ozempic revolutionized diabetes and weight loss, orexin-based therapies might tackle sleep disorders, depression, and more. This Economist piece explores the science and the commercial stakes.
Drugmakers are now betting that two other peptides, the orexins, could follow a similar path for a variety of brain-related ailments.